DV Trading LLC Makes New $1.16 Million Investment in Vaxcyte, Inc. $PCVX

DV Trading LLC acquired a new stake in Vaxcyte, Inc. (NASDAQ:PCVX) in the first quarter, HoldingsChannel reports. The institutional investor acquired 20,000 shares of the company’s stock, valued at approximately $1,162,000.

Several other large investors also recently modified their holdings of PCVX. Royal Bank of Canada lifted its stake in shares of Vaxcyte by 115.2% in the first quarter. Royal Bank of Canada now owns 29,471 shares of the company’s stock worth $1,113,000 after acquiring an additional 15,774 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in Vaxcyte in the first quarter valued at about $219,000. Caxton Associates LLP acquired a new stake in Vaxcyte during the 1st quarter valued at approximately $226,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its stake in Vaxcyte by 8.7% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 513,998 shares of the company’s stock valued at $19,409,000 after purchasing an additional 41,034 shares in the last quarter. Finally, Cetera Investment Advisers increased its holdings in Vaxcyte by 13.8% during the 2nd quarter. Cetera Investment Advisers now owns 7,681 shares of the company’s stock worth $250,000 after purchasing an additional 932 shares during the last quarter. 96.78% of the stock is currently owned by institutional investors and hedge funds.

Vaxcyte Stock Down 3.4%

NASDAQ:PCVX opened at $54.08 on Friday. The company has a market cap of $7.81 billion, a PE ratio of -7.86 and a beta of 1.22. The business’s 50 day moving average is $53.25 and its two-hundred day moving average is $54.89. Vaxcyte, Inc. has a 52 week low of $29.08 and a 52 week high of $65.00.

Vaxcyte (NASDAQ:PCVX) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($2.30) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.74) by ($0.56). During the same quarter last year, the company posted ($1.04) earnings per share. As a group, sell-side analysts expect that Vaxcyte, Inc. will post -7.91 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Grant Pickering sold 2,000 shares of the firm’s stock in a transaction dated Monday, July 27th. The shares were sold at an average price of $55.65, for a total value of $111,300.00. Following the transaction, the chief executive officer directly owned 133,215 shares in the company, valued at approximately $7,413,414.75. This trade represents a 1.48% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, COO Jim Wassil sold 2,250 shares of Vaxcyte stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $56.33, for a total transaction of $126,742.50. Following the completion of the transaction, the chief operating officer directly owned 156,760 shares of the company’s stock, valued at $8,830,290.80. This trade represents a 1.42% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 91,396 shares of company stock valued at $4,975,725. Company insiders own 3.30% of the company’s stock.

Wall Street Analysts Forecast Growth

PCVX has been the subject of a number of recent analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Vaxcyte in a research report on Monday, July 6th. Zacks Research cut shares of Vaxcyte from a “hold” rating to a “strong sell” rating in a report on Tuesday, July 14th. Finally, Wall Street Zen cut shares of Vaxcyte from a “sell” rating to a “strong sell” rating in a report on Tuesday, April 28th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Vaxcyte currently has a consensus rating of “Hold” and a consensus target price of $86.00.

About Vaxcyte

Vaxcyte, Inc (NASDAQ: PCVX) is a clinical-stage biotechnology company focused on developing a new generation of preventive vaccines aimed at combating serious bacterial diseases. Headquartered in San Carlos, California, Vaxcyte leverages proprietary conjugation technologies to design and manufacture multivalent vaccines targeting pathogens for which there remain significant unmet medical needs. The company’s platform is intended to streamline the production of conjugate vaccines by improving antigen presentation and broadening strain coverage compared with conventional approaches.

Vaxcyte’s lead candidate, VAX-24, is a 24-valent pneumococcal conjugate vaccine designed to protect against 24 serotypes of Streptococcus pneumoniae.